User login
Key clinical point: Rheumatoid arthritis patients taking a combination of methotrexate and JAKi showed no increased risk of malignancy compared to RA patients on methotrexate alone.
Major finding: No significant differences in overall malignancy appeared between methotrexate /JAKi combination patients compared to methotrexate-only patients (risk ratio 1.42); no differences appeared between the groups for nonmelanoma skin cancer (RR 1.44), malignancies excluding nonmelanoma skin cancer (RR 1.12), serious adverse events (RR 1.15), or deaths (RR 1.99).
Study details: The data come from a meta-analysis of 13 randomized, controlled trials with a total of 6,911 RA patients who received methotrexate and Janus kinase inhibitors (JAKi)
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Solipuram V et al. Auto Immune Highlights. 2021 Apr 28. doi: 10.1186/s13317-021-00153-5.
Key clinical point: Rheumatoid arthritis patients taking a combination of methotrexate and JAKi showed no increased risk of malignancy compared to RA patients on methotrexate alone.
Major finding: No significant differences in overall malignancy appeared between methotrexate /JAKi combination patients compared to methotrexate-only patients (risk ratio 1.42); no differences appeared between the groups for nonmelanoma skin cancer (RR 1.44), malignancies excluding nonmelanoma skin cancer (RR 1.12), serious adverse events (RR 1.15), or deaths (RR 1.99).
Study details: The data come from a meta-analysis of 13 randomized, controlled trials with a total of 6,911 RA patients who received methotrexate and Janus kinase inhibitors (JAKi)
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Solipuram V et al. Auto Immune Highlights. 2021 Apr 28. doi: 10.1186/s13317-021-00153-5.
Key clinical point: Rheumatoid arthritis patients taking a combination of methotrexate and JAKi showed no increased risk of malignancy compared to RA patients on methotrexate alone.
Major finding: No significant differences in overall malignancy appeared between methotrexate /JAKi combination patients compared to methotrexate-only patients (risk ratio 1.42); no differences appeared between the groups for nonmelanoma skin cancer (RR 1.44), malignancies excluding nonmelanoma skin cancer (RR 1.12), serious adverse events (RR 1.15), or deaths (RR 1.99).
Study details: The data come from a meta-analysis of 13 randomized, controlled trials with a total of 6,911 RA patients who received methotrexate and Janus kinase inhibitors (JAKi)
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Solipuram V et al. Auto Immune Highlights. 2021 Apr 28. doi: 10.1186/s13317-021-00153-5.